Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced...
Ronald A. Martell Named Chief Executive Officer Michael S. Perry, DVM, Ph.D., Named President and Chief Medical Officer SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Poniard...
SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) today provided an overview of its 2010 corporate, clinical and regulatory goals for...
-- Company to Host Conference Call and Webcast Today at 8:00 a.m. ET -- SOUTH SAN FRANCISCO, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) today announced...
SOUTH SAN FRANCISCO, Calif., Nov. 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) today announced that the Company will hold a teleconference and webcast at 8:00 a.m...
- Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD), a biopharmaceutical company focused...
SOUTH SAN FRANCISCO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a...
-- Event Enables Overall Survival Analysis of Registration SPEAR Trial -- SOUTH SAN FRANCISCO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) today...
SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 196 | 0.0001 | CS |
| 52 | 9.9E-5 | 9900 | 1.0E-6 | 0.000101 | 1.0E-6 | 3236 | 2.311E-5 | CS |
| 156 | -0.0099 | -99 | 0.01 | 0.01 | 1.0E-6 | 1588 | 3.654E-5 | CS |
| 260 | -0.0126 | -99.2125984252 | 0.0127 | 0.122 | 1.0E-6 | 4367 | 0.04694882 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
